The World Health Organization estimates that dengue virus causes more than 50 million cases of dengue fever a year. Dengue virus infection is the leading cause of hospitalization and death in children of most tropical Asian countries. There are four different serotypes of dengue virus. Most cases of dengue hemorrhagic fever/dengue shock syndrome are caused by secondary infection with a dengue serotype different from the first serotype the individual was infected with. A vaccine that would be effective in preventing infection by multiple dengue serotypes is desirable. The purpose of this study is to determine the safety of and immune response to two different dengue virus vaccines in individuals who have been previously vaccinated against a different serotype.. This study will last at least 42 days. Participants will be recruited from a database of previous dengue vaccine recipients and will be stratified by the type of vaccine previously received. Participants assigned to Cohort 1 and Cohort 2 ...
It is known that antibodies to dengue viruses at subneutralizing concentrations enhance dengue virus infection of Fc gamma R+ cells. This phenomenon called antibody-dependent enhancement (ADE) occurs when virus-antibody complexes bind to the Fc gamma R via the Fc portion of the Ig. It has been hypothesized that ADE may be responsible for the pathogenesis of the severe manifestations of dengue virus infection including dengue hemorrhagic fever/dengue shock syndrome. To further analyze the mechanisms of ADE, we prepared bispecific antibodies by chemically cross-linking antidengue virus antibodies to antibodies specific for Fc gamma RI or Fc gamma RII and the non-Fc R molecules beta2 microglobulin, CD15 or CD33 and examined whether these bispecific antibodies could enhance infection. Bispecific antibodies targeting dengue virus to Fc gamma RI or Fc gamma RII enhanced dengue virus infection, consistent with previous reports using conventional antibodies. Furthermore, bispecific antibodies targeting ...
Dengue viruses cause dengue fever and the more severe condition, dengue hemorrhagic fever/shock syndrome. Dengue viruses are common in most tropical and subtropical regions of the world and infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries. For these reasons, the World Health Organization (WHO) has made the development of a dengue virus vaccine a top priority. This study will evaluate the safety and immunogenicity of two doses of a live attenuated, tetravalent dengue virus vaccine called TetraVax-DV in healthy adults (18-50 years old) who have previously been infected with a dengue virus or other flavivirus or have previously received a flavivirus vaccine. Two different formulations of the TetraVax-DV vaccine will be evaluated.. Participants will be randomly assigned to receive one of two admixtures of the TetraVax-DV vaccine or a placebo. At a baseline study visit (Day 0), participants will undergo a medical history ...
The protective immunity conferred by a set of recombinant vaccinia viruses containing the entire coding sequence of dengue virus type 4 nonstructural glycoprotein NS1 plus various flanking sequences was evaluated by using a mouse encephalitis model. Mice immunized with recombinant vNS1-NS2a, which expresses authentic NS1, were solidly protected against intracerebral dengue virus challenge. However, mice immunized with recombinants vNS1-15%NS2a and vRSVG/NS1-15%NS2a, which express aberrant forms of NS1, were only partially protected (63 to 67% survival rate). Serologic analysis showed that mice immunized with vNS1-NS2a developed high titers of antibodies to NS1 as measured by radioimmunoprecipitation, enzyme-linked immunosorbent assay, and complement-mediated cytolytic assays. In addition, a pool of sera from these animals was protective in a passive transfer experiment. Lower titers of NS1-specific antibodies were detected in sera of animals immunized with vNS1-15%NS2a or vRSVG/NS1-15%NS2a by ...
TY - JOUR. T1 - Retraction. T2 - Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity (Proc Natl Acad Sci USA (2014) 111, (1939-1944) DOI: 10.1073/pnas.1317350111). AU - Messer, William. AU - De Alwis, Ruklanthi. AU - Yount, Boyd L.. AU - Royal, Scott R.. AU - Huynh, Jeremy P.. AU - Smith, Scott A.. AU - Crowe, James E.. AU - Doranz, Benjamin J.. AU - Kahle, Kristen M.. AU - Pfaff, Jennifer M.. AU - White, Laura J.. AU - Sariol, Carlos A.. AU - De Silva, Aravinda M.. AU - Baric, Ralph S.. PY - 2015/5/19. Y1 - 2015/5/19. UR - http://www.scopus.com/inward/record.url?scp=84929484676&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84929484676&partnerID=8YFLogxK. U2 - 10.1073/pnas.1506982112. DO - 10.1073/pnas.1506982112. M3 - Article. C2 - 25941397. AN - SCOPUS:84929484676. VL - 112. SP - E2738. JO - Proceedings of the National Academy of Sciences of the United States of America. JF - Proceedings of the National Academy of ...
Research recently published in PLoS Medicine challenges the dogma of the antibody-dependent enhancement model (ADE) for the development of dengue hemorrhagic fever (DHF). Dengue virus infection usually causes a severe flu like illness, although symptoms may be mild in young children. DHF, however, is a severe and sometimes fatal complication of dengue virus infection that affects about half a million people every year. DHF patients usually fall into two groups; children and adults who become infected with a second dengue virus serotype after an initial primary dengue virus infection with a different serotype, and infants with primary dengue virus infections born to mothers who have some dengue virus immunity. The current model for development of DHF in infants around 6 months old is that anti-dengue virus antibodies transferred from a dengue-immune mother to her child somehow enhance dengue virus infection, resulting in more severe symptoms (the antibody-dependent enhancement model). A ...
Dengue virus infects approximately 100 million people annually, but there is no available therapeutic treatment. The mimetic peptide, DN59, consists of residues corresponding to the membrane interacting, amphipathic stem region of the dengue virus envelope (E) glycoprotein. This peptide is inhibitory to all four serotypes of dengue virus, as well as other flaviviruses. Cryo-electron microscopy image reconstruction of dengue virus particles incubated with DN59 showed that the virus particles were largely empty, concurrent with the formation of holes at the five-fold vertices. The release of RNA from the viral particle following incubation with DN59 was confirmed by increased sensitivity of the RNA genome to exogenous RNase and separation of the genome from the E protein in a tartrate density gradient. DN59 interacted strongly with synthetic lipid vesicles and caused membrane disruptions, but was found to be non-toxic to mammalian and insect cells. Thus DN59 inhibits flavivirus infectivity by interacting
We analyzed dengue virus-specific CD4+ CD8- cytotoxic T lymphocytes (CTL) at the clonal level to further understand their role in dengue virus infections. Stimulation of peripheral blood mononuclear cells from two dengue virus type 4 (D4V)-immune donors with live D4V or noninfectious D4V antigen generated 17 HLA class II-restricted CD4+ CTL capable of specific lysis of dengue virus antigen-treated autologous lymphoblastoid cell lines. Thirteen clones were D4V specific, three clones were cross-reactive for D2V and D4V, and one clone was cross-reactive for D1V, D3V, and D4V. Antigen recognition by six D4V-specific clones and three D2V- and D4V-cross-reactive clones was restricted by HLA-DR7. Five D4V-specific CD4+ CTL clones lysed autologous lymphoblastoid cell lines infected with a dengue virus-vaccinia virus recombinant containing the E gene of D4V, whereas three serotype-cross-reactive CTL clones did not. These results indicate that E-specific clones are serotype specific and HLA-DR7 restricted in
Link to Pubmed [PMID] - 27526393. Curr Opin Virol 2016 Aug;21:47-53. To date, dengue virus evolution has mainly been addressed by studies conducted at the between-host level. Like other pathogens with high mutation rate and rapid replication, dengue viruses also evolve during the course of an infection. Over the last few years, the advent of deep-sequencing technologies has facilitated studies of dengue virus populations at the within-host level. Here, we review recent advances on the evolutionary dynamics of dengue virus populations within their mosquito vector. We discuss how identifying the evolutionary forces acting on dengue virus populations within the mosquito can shed light on the processes underlying vector-virus interactions and the evolution of epidemiologically relevant traits.. http://www.ncbi.nlm.nih.gov/pubmed/27526393 ...
Title: Steady-State Cleavage Kinetics for Dengue Virus Type 2 Ns2b-Ns3(Pro) Serine Protease With Synthetic Peptides. VOLUME: 10 ISSUE: 1. Author(s):Rabuesak Khumthong, Pornwarat Niyomrattanakit, Santad Chanprapaph, Chanan Angsuthanasombat, Sakol Panyim and Gerd Katzenmeier. Affiliation:Laboratory of Molecular Virology, Institute of Molecular Biology and Genetics, Mahidol University, SalayaCampus, Phutthamonthon No. 4 Rd., Nakornpathom 73170, Thailand. Keywords:dengue virus, ns2b-ns3, serine protease, peptide, substrate, assay, kinetic, cleavage kinetics. Abstract: The N-terminal part of the NS3 protein from dengue virus contains a trypsin-like serine protease responsible for processing the nonstructural region of the viral polyprotein. Enzymatic activity of the NS2B-NS3(pro) precursor incorporating a full-length NS2B cofactor of dengue virus type 2 was examined by using synthetic dodecamer peptide substrates encompassing native cleavage sequences of the NS2A/NS2B, NS2B / NS3, NS3 / NS4A and NS4B ...
Everyone knows how mosquitos can wreck an end-of-summer picnic. But in some climates, these pesky intruders persist and carry a variety of detrimental diseases-some with no preventative vaccines or targeted therapies. One such passenger is dengue virus (DENV), which infects up to 400 million people each year and comes in several serotypes (1 to 4) and disease presentations-from mild infection to severe disease and sometimes death. But to treat or prevent dengue requires that we have a more complete picture of the disease pathology. Now, Modhiran et al. and Beatty et al. describe the results of in vitro and in vivo experiments that point to circulating dengue virus non-structural protein 1 (NS1) and the innate immune Toll-like receptor 4 (TLR4) as a focus for basic scientists as well as vaccine and drug developers.. DENV infection protects a patient from future reinfection with the same DENV serotype as well as producing temporary immune protection from severe dengue disease caused by a different ...
The relationship between the percent phagocytosis of platelets by differentiated THP-1 cells was examined using flowcytometry and the peripheral platelet counts as well as platelet-associated IgG (PAIgG) in 36 patients with secondary dengue virus (DV) infections. The percent phagocytosis and the levels of PAIgG were significantly increased in these patients during the acute phase compared with the healthy volunteers. The increased percent phagocytosis and PAIgG found during the acute phase significantly decreased during the convalescent phase. An inverse correlation between platelet count and the percent phagocytosis (P = 0.011) and the levels of PAIgG (P = 0.041) was found among these patients during the acute phase. No correlation was found, however, between the percent phagocytosis and the levels of PAIgG. Our present data suggest that accelerated platelet phagocytosis occurs during the acute phase of secondary DV infections, and it is one of the mechanisms of thrombocytopenia in this disease.
Although Wolbachia can grow in a variety of tissues, it has a particular attachment to gonads and reproduces itself through infecting female eggs.. "To ensure its spread, Wolbachia uses several methods, including ensuring that all the male offspring die, causing infected males to develop as females or even allowing females to produce fertile offspring without ever mating," continues Dr. Timmer. "Once in cells, Wolbachia seems to interfere with many (but not all) other pathogens, including dengue virus. Were just not sure how this happens. Theres some signs that Wolbachia competes with other parasites, that it activates the insect version of an immune system, and that it activates other defenses in the mosquitoes. But which (if any) of these is involved in limiting dengue virus isnt clear. But it is clear that mosquitoes with Wolbachia growing in them produce far less dengue virus, and thus pose less of a risk of passing the virus on to new victims.". Elaborating on the dengue threat, Prof. ...
Recombinant Dengue virus 2 Dengue Virus 2 envelope protein is an Escherichia coli Protein fragment 298 to 400 aa range, | 95% purity and validated in SDS-PAGE.
Gentaur molecular products has all kinds of products like :search , Ray Biotech \ Recombinant Dengue Virus Envelope Protein-3 \ 228-10312-1 for more molecular products just contact us
Gentaur molecular products has all kinds of products like :Ray_Biotech , Ray Biotech \ Recombinant Dengue Virus Envelope \ 228-10309-3 for more molecular products just contact us
Detection of dengue virus nucleic acid in serum is suggestive of recent exposure and acute infection with dengue virus.. The presence of dengue virus nucleic acid in serum can be used as a marker for acute-phase infection. Patients with a history of symptoms for more than 1 week may be negative by molecular tests (ie, real-time PCR) and may require serologic testing to confirm the diagnosis of dengue virus infection.. ...
Abstract. After the report of an outbreak of dengue virus serotype 2 in 2014 in Nampula and Pemba cities, northern Mozambique, a surveillance system was established by the National Institute of Health. A study was performed during 2015-2016 to monitor the trend of the outbreak and confirm the circulating serotype of dengue virus (DENV). After the inclusion of consenting patients who met the case definition, samples from 192 patients were tested for the presence of nonstructural protein 1 antigen, and 60/192 (31%) samples were positive. Further analysis included DENV IgM antibodies, with 39 (20%) IgM positive cases. Reverse transcriptase (RT) PCR was performed for identification of the prevailing DENV serotype; 21/23 tested samples were DENV-2 positive, with DENV-2 present in both affected cities. When sequencing DENV, phenotype Cosmopolitan was identified. The surveillance indicates ongoing spread of DENV-2 in northern Mozambique 2 years after the first report of the outbreak.
TY - JOUR. T1 - Prolonged persistence of IgM against dengue virus detected by commonly used commercial assays. AU - Chien, Yu-Wen. AU - Liu, Zi Hu. AU - Tseng, Fan Chen. AU - Ho, Tzu Chuan. AU - Guo, How-Ran. AU - Ko, Nai-Ying. AU - Ko, Wen-Chien. AU - Perng, Guey-Chuen. PY - 2018/4/2. Y1 - 2018/4/2. N2 - Background: Initial symptoms of dengue fever are non-specific, and thus definite diagnosis requires laboratory confirmation. Detection of IgM against dengue virus (DENV) has become widely used for dengue diagnosis. Understanding the persistence of anti-DENV IgM in subjects after acute infection is essential in order to interpret test results correctly. Although the longevity of anti-DENV IgM has been vehemently investigated in symptomatic children, anti-DENV IgM persistence in adults and in asymptomatically infected people have seldom been reported. Methods: We prospectively investigated 44 adults with detectable anti-DENV IgM in a serosurvey conducted in the 2015 dengue epidemic in Tainan, ...
Dengue is a major mosquito-borne disease currently with no effective antiviral or vaccine available. Effort to find antivirals for it has focused on bioflavonoids, a plant-derived polyphenolic compounds with many potential health benefits. In the present study, antiviral activity of four types of bioflavonoid against dengue virus type -2 (DENV-2) in Vero cell was evaluated. Anti-dengue activity of these compounds was determined at different stages of DENV-2 infection and replication cycle. DENV replication was measured by Foci Forming Unit Reduction Assay (FFURA) and quantitative RT-PCR. Selectivity Index value (SI) was determined as the ratio of cytotoxic concentration 50 (CC50) to inhibitory concentration 50 (IC50) for each compound. The half maximal inhibitory concentration (IC50) of quercetin against dengue virus was 35.7 μg mL-1 when it was used after virus adsorption to the cells. The IC50 decreased to 28.9 μg mL-1 when the cells were treated continuously for 5 h before virus infection and up to
Dengue virus is coated by an icosahedral shell of 90 envelope protein dimers that convert to trimers at low pH and promote fusion of its membrane with the membrane of the host endosome. We provide the first estimates for the free energy barrier and minimum for two key steps in this process: host membrane bending and protein-membrane binding. Both are studied using complementary membrane elastic, continuum electrostatics and all-atom molecular dynamics simulations. The predicted host membrane bending required to form an initial fusion stalk presents a 22-30 kcal/mol free energy barrier according to a constrained membrane elastic model. Combined continuum and molecular dynamics results predict a 15 kcal/mol free energy decrease on binding of each trimer of dengue envelope protein to a membrane with 30% anionic phosphatidylglycerol lipid. The bending cost depends on the preferred curvature of the lipids composing the host membrane leaflets, while the free energy gained for protein binding depends ...
TY - JOUR. T1 - Membrane topology and function of dengue virus NS2A protein. AU - Xie, Xuping. AU - Gayen, Shovanlal. AU - Kang, Cong Bao. AU - Yuan, Zhiming. AU - Shi, Pei Yong. PY - 2013/4/1. Y1 - 2013/4/1. N2 - Flavivirus nonstructural protein 2A (NS2A) is a component of the viral replication complex that functions in virion assembly and antagonizes the host immune response. Although flavivirus NS2A is known to associate with the endoplasmic reticulum (ER) membrane, the detailed topology of this protein has not been determined. Here we report the first topology model of flavivirus NS2A on the ER membrane. Using dengue virus (DENV) NS2A as a model, we show that (i) the N-terminal 68 amino acids are located in the ER lumen, with one segment (amino acids 30 to 52) that interacts with ER membrane without traversing the lipid bilayer; (ii) amino acids 69 to 209 form five transmembrane segments, each of which integrally spans the ER membrane; and (iii) the C-terminal tail (amino acids 210 to 218) ...
Imported dengue cases originating from the Madeiran outbreak are increasingly reported. In 2012 five Finnish travellers returning from Madeira were diagnosed with dengue fever. Viral sequence data was obtained from two patients. The partial C-preM sequences (399 and 396 bp respectively) were found similar to that of an autochthonous case from Madeira. The partial E-gene sequence (933 bp) which was identical among the two patients grouped phylogenetically with South American strains of dengue virus serotype 1.. More …. ...
BACKGROUND: Dengue is one of the most important human diseases transmitted by an arthropod vector and the incidence of dengue virus infection has been increasing - over half the worlds population now live in areas at risk of infection. Most infections are asymptomatic, but a subset of patients experience a potentially fatal shock syndrome characterised by plasma leakage. Severe forms of dengue are epidemiologically associated with repeated infection by more than one of the four dengue virus serotypes. Generally attributed to the phenomenon of antibody-dependent enhancement, recent observations indicate that T-cells may also influence disease phenotype. METHODS AND FINDINGS: Virus-specific cytotoxic T lymphocytes (CTL) showing high level cross reactivity between dengue serotypes could be expanded from blood samples taken during the acute phase of secondary dengue infection. These could not be detected in convalescence when only CTL populations demonstrating significant serotype specificity were
The discovery, reported this week in eLife, illuminates a biological mechanism that could turn out to be a general indicator and modifier of dengue transmission risk in the wild.. If this common fungus proves to have a significant impact on mosquitoes ability to transmit dengue virus to people in endemic areas, then we can start to think about ways to translate this knowledge into specific anti-dengue strategies, says George Dimopoulos, PhD, professor in the Bloomberg Schools Department of Molecular Microbiology and Immunology.. Scientists have estimated that hundreds of millions of people suffer dengue virus infections--known as dengue fever--in tropical regions each year. Dengue infections can involve severe joint and muscle pain and have also been termed breakbone fever. Although most cases are mild enough that they are never clinically reported, some take a severe hemorrhagic form that require hospitalization and are often fatal.. Dimopoulos and colleagues have discovered certain ...
... cause of arboviral diseases in humans. on polyclonal sera and B-cells following natural DENV contamination has tremendous implications for better immunogen design for a safe and effective dengue vaccine. This review outlines the progress in our understanding of mouse mAbs, human mAbs, and polyclonal sera against DENV precursor and envelope membrane protein, two surface protein involved with vaccine development, pursuing natural infections; analyses of the discoveries have supplied valuable understanding into brand-new strategies concerning molecular technology to induce stronger neutralizing antibodies and much less BGJ398 ic50 improving antibodies for next-generation dengue vaccine advancement. of the family members 30 CrR (45%)7 ND55425253DIII: lr, str A and str G15 solid NT mAbs14 anti-DIIIShrestha et al., 2010DENV23320 TS (61%)11 CrR (33%)2 ND8621115DIII: lr, CCL and str A, DI: lr,DII: lr, di and FL24 solid NT mAbs11 anti-DIII, 13 ...
Dengue is the most prevalent mosquito-borne viral infection worldwide and is the leading cause of illness and death in tropical/subtropical areas (,390 million people are infected). There are no approved vaccines or drugs against the virus. While most infections resolve without medical intervention, a significant fraction of dengue patients develop hemorrhagic fever and shock syndrome, which if untreated can be fatal. Early supportive care is critical for management of the fever and maintaining the blood volume during hemorrhage. Because the initial symptoms of dengue are similar to many other mosquito transmitted viral infections, early and accurate diagnosis of the disease is critical for these patients.. Generally, current dengue virus assays are not sensitive enough, too expensive and/or time-consuming resulting in delayed/misguided medical intervention in up to 50% of cases. In developing countries, the ease of access, availability of required infrastructure and the cost of diagnosis are ...
Dengue virus (DENV), the causative agent of dengue fever (DF), is one of the most important mosquito-borne viruses that can infect humans. Although much effort has been made on prevention and control of dengue, there are currently no anti-viral drugs or worldwide approved vaccines yet. In this study, we immunized six-week-old Balb/c mice with DNA vaccine candidates E and NS1-2a of DENV serotype 2 or the combination of them (E+NS1-2a) via an electroporation (EP)-assisted intramuscular gene delivery system and evaluated the immune response and protection. The highest specific antibody titres and cytokine levels secreted by splenocytes as well as the highest survival rate were observed in the E+NS1-2a group, followed by E group and NS1-2a group. Our data suggested that the combination of E and NS1-2a delivered by EP may be a superior preventive strategy against DENV.
Dengue Virus 3, 1 mg. The dengue virus is responsible for the tropical and sub-tropical diseases, dengue (DF) and dengue haemorrhagic fever (DHF), transmitted to individuals through the bite of the Aedes mosquito.
Dengue virus NS3 protein antibody [GT2811] (Dengue virus 2 Nonstructural protein NS3) for ICC/IF, WB. Anti-Dengue virus NS3 protein mAb (GTX629477) is tested in Dengue virus samples. 100% Ab-Assurance.
Dengue fever is caused by four distinct serotypes of the dengue virus (DENV1-4), and is estimated to affect over 500 million people every year. Presently, there are no vaccines or antiviral treatments for this disease. Among the possible targets to fight dengue fever is the viral NS3 protease (NS3PRO), which is in part responsible for viral processing and replication. It is now widely recognized that virtual screening campaigns should consider the flexibility of target protein by using multiple active conformational states. The flexibility of the DENV NS3PRO could explain the relatively low success of previous virtual screening studies. In this first work, we explore the DENV NS3PRO conformational states obtained from molecular dynamics (MD) simulations to take into account protease flexibility during the virtual screening/docking process. To do so, we built a full NS3PRO model by multiple template homology modeling. The model comprised the NS2B cofactor (essential to the NS3PRO activation), a glycine
Asias burgeoning airline network is helping spread the dengue virus (DENV) across the continent says this new study. It found that air traffic volumes and connections explain DENV migration across Asia better than socio-economic and environmental factors like gross domestic product (GDP) and conducive temperatures. Central air hubs such as those in China, India, Singapore and Thailand contribute more to the diffusion of dengue compared to less busy routes. The findings suggest that future trends in global mobility could potentially accelerate the appearance and diffusion of DENV worldwide.. ...
Artistic rendering of dengue virus immediately prior to the fusion of the viral lipid membrane (bottom) to the endosomal membrane of the host cell (top). Two dengue virus envelope protein trimers are shown (in surface representation) on either side of a nascent membrane fusion stalk. Completion of membrane fusion requires the alpha-helical "stem" regions (shown in worm representation) to anneal onto the core of the E trimers. The image is based on crystal structures of dengue virus E protein in the postfusion conformation determined in the Modis Laboratory. Image created by Janet Iwasa and Gaël McGill, Digizyme, Inc.. Vinod Nayak, Moshe Dessau, Kaury Kucera, Karen Anthony, Michel Ledizet & Yorgo Modis (2009). Crystal structure of dengue type 1 envelope protein in the postfusion conformation and its implication for receptor binding, membrane fusion and antibody recognition. J. Virol., 83, 4338-44.. Yorgo Modis, Steven Ogata, David Clements & Stephen C. Harrison (2004). Structure of the dengue ...
TY - JOUR. T1 - Proteomic analysis of endothelial cell autoantigens recognized by anti-dengue virus nonstructural protein 1 antibodies. AU - Cheng, Hsien Jen. AU - Lin, Chiou Feng. AU - Lei, Huan Yao. AU - Liu, Hsiao Sheng. AU - Yeh, Trai Ming. AU - Luo, Yueh Hsia. AU - Lin, Yee Shin. PY - 2009/1. Y1 - 2009/1. N2 - We previously showed the occurrence of autoimmune responses in dengue virus (DV) infection, which has potential implications for the pathogenesis of dengue hemorrhagic syndrome. In the present study, we have used a proteomic analysis to identify several candidate proteins on HMEC-1 endothelial cells recognized by anti-DV nonstructural protein 1 (NS1) antibodies. The target proteins, including ATP synthase β chain, protein disulfide isomerase, vimentin, and heat shock protein 60, co-localize with anti-NS1 binding sites on nonfixed HMEC-1 cells using immunohistochemical double staining and confocal microscopy. The cross-reactivity of anti-target protein antibodies with HMEC-1 cells was ...
Dengue Virus Serotype 1 Antibody (OANB00114) | Monoclonal Antibody | Clone: ME1.G6.C12 | Application: WB, ELISA | Species reactivity: Viral | Alias:
Creative Biostructure produces Dengue Virus Serotype 3 VLP (E, M, preM Proteins) using advanced human and insect cells recombinant expression systems.
Dengue virus (DV) is a flavivirus and infects mammalian cells through mosquito vectors. This study investigates the roles of domain III of DV type 2 envelope protein (EIII) in DV binding to the host cell. Recombinant EIII interferes with DV infection to BHK21 and C6/36 cells by blocking dengue virion adsorption to these cells. Inhibition of EIII on BHK21 cells was broad with no serotype specificity; however, inhibition of EIII on C6/36 cells was relatively serotype specific. Soluble heparin completely blocks binding of EIII to BHK21 cells, suggesting that domain III binds mainly to cell surface heparan sulfates. This suggestion is supported by the observation that EIII binds very weakly to gro2C and sog9 mutant mammalian cell lines that lack heparan sulfate. In contrast, heparin does not block binding of EIII to mosquito cells. Furthermore, a synthetic peptide that includes amino acids (aa) 380 to 389 of EIII, IGVEPGQLKL, inhibits binding of EIII to C6/36 but not BHK21 cells. This peptide ...
Inquiry (45981) for Abcams Recombinant Dengue Virus 2 NS1 glycoprotein. Our in-house scientific support team are here to help you with any technical questions or queries
Dengue virus prM protein antibody for ICC/IF, WB. Anti-Dengue virus prM protein pAb (GTX128093) is tested in Dengue virus samples. 100% Ab-Assurance.
The flavivirus envelope protein domain III (EDIII) was an effective immunogen against dengue virus (DENV) and other related flaviviruses. Whether this can be applied to the Zika virus (ZIKV) vaccinology remains an open question. Here, we tested the efficacy of ZIKV-EDIII against ZIKV infection, using several vaccine platforms that present the antigen in various ways. We provide data demonstrating that mice vaccinated with a ZIKV-EDIII as DNA or protein-based vaccines failed to raise fully neutralizing antibodies and did not control viremia, following a ZIKV challenge, despite eliciting robust antibody responses. Furthermore, we showed that ZIKV-EDIII encoded in replication-deficient Chimpanzee adenovirus (ChAdOx1-EDIII) elicited anti-ZIKV envelope antibodies in vaccinated mice but also provided limited protection against ZIKV in two physiologically different mouse challenge models. Taken together, our data indicate that contrary to what was shown for other flaviviruses like the dengue virus, which has
Dengue virus type 4 ATCC ® VR-1726™ Designation: Monoclonal Anti-Dengue virus type 4 E protein, clone E62 (produced in vitro ) Application: Emerging infectious disease research
Dengue virus type 4 ATCC ® VR-1712™ Designation: Monoclonal Anti-Dengue virus type 4 E protein, clone E2 (produced in vitro ) Application:
A DNA tetrahedron having a single-strand DNA edge was used to detect a dengue virus RNA sequence. Novel tandem toehold-mediated displacement reactions (tTMDR) were developed to amplify the fluorescence signal from the DNA tetrahedron. Using an excess of the DNA tetrahedron each target RNA was recycled about 103 tim
We characterized 11 dengue virus (DENV) isolates obtained from Finnish travelers during 2000-2005 using monoclonal antibodies and phylogenetic analysis. The analysis of DENV isolated from travelers contributes to the global picture of strain distribution and circulation. The isolates included all serotypes, including a DENV-2 isolate from Ghana.
We characterized 11 dengue virus (DENV) isolates obtained from Finnish travelers during 2000-2005 using monoclonal antibodies and phylogenetic analysis. The analysis of DENV isolated from travelers contributes to the global picture of strain distribution and circulation. The isolates included all serotypes, including a DENV-2 isolate from Ghana ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
TY - JOUR. T1 - Full-length dengue virus RNA-dependent RNA polymerase-RNA/DNA complexes. T2 - Stoichiometries, intrinsic affinities, cooperativities, base, and conformational specificities. AU - Szymanski, Michal R.. AU - Jezewska, Maria J.. AU - Bujalowski, Paul J.. AU - Bussetta, Cecile. AU - Ye, Mengyi. AU - Choi, Kyung H.. AU - Bujalowski, Wlodzimierz. PY - 2011/9/23. Y1 - 2011/9/23. N2 - Fundamental aspects of interactions of the Dengue virus type 3 full-length polymerase with the single-stranded and double-stranded RNA and DNA have been quantitatively addressed. The polymerase exists as a monomer with an elongated shape in solution. In the absence of magnesium, the total site size of the polymerase-ssRNA complex is 26 ± 2 nucleotides. In the presence of Mg 2+, the site size increases to 29 ± 2 nucleotides, indicating that magnesium affects the enzyme global conformation. The enzyme shows a preference for the homopyrimidine ssRNAs. Positive cooperativity in the binding to homopurine ...
Dengue virus (DENV) has spread through most tropical and subtropical areas of the world and represents a serious public health problem. The control of DENV infection has not yet been fully successful due to lack of effective therapeutics or vaccines. Nevertheless, a better understanding of the immune responses against DENV infection may reveal new strategies for eliciting and improving antiviral immunity. T cells provide protective immunity against various viral infections by generating effector cells that cooperate to eliminate antigens and memory cells that can survive for long periods with enhanced abilities to control recurring pathogens. Following activation, CD8 T cells can migrate to sites of infection and kill infected cells, whereas CD4 T cells contribute to the elimination of pathogens by trafficking to infected tissues and providing help to innate immune responses, B cells, as well as CD8 T cells. However, it is now evident that CD4 T cells can also perform cytotoxic functions and induce
Link to Pubmed [PMID] - 28534525. Nat Commun 2017 May;8:15411. A problem in the search for an efficient vaccine against dengue virus is the immunodominance of the fusion loop epitope (FLE), a segment of the envelope protein E that is buried at the interface of the E dimers coating mature viral particles. Anti-FLE antibodies are broadly cross-reactive but poorly neutralizing, displaying a strong infection enhancing potential. FLE exposure takes place via dynamic breathing of E dimers at the virion surface. In contrast, antibodies targeting the E dimer epitope (EDE), readily exposed at the E dimer interface over the region of the conserved fusion loop, are very potent and broadly neutralizing. We here engineer E dimers locked by inter-subunit disulfide bonds, and show by X-ray crystallography and by binding to a panel of human antibodies that these engineered dimers do not expose the FLE, while retaining the EDE exposure. These locked dimers are strong immunogen candidates for a next-generation ...
Article: Zhang B, Salieb-Beugelaar GB, Nigo MM, Weidmann M & Hunziker P (2015) Diagnosing dengue virus infection: rapid tests and the role of micro/nanotechnologies. |i|Nanomedicine: Nanotechnology, Biology and Medicine|/i|, 11 (7), pp. 1745-1761. https://doi.org/10.1016/j.nano.2015.05.009